vs
MIMEDX GROUP, INC.（MDXG）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是MIMEDX GROUP, INC.的1.7倍（$200.5M vs $118.1M），MIMEDX GROUP, INC.净利率更高（12.9% vs 2.2%，领先10.6%），MIMEDX GROUP, INC.同比增速更快（27.1% vs 5.2%），过去两年MIMEDX GROUP, INC.的营收复合增速更高（18.1% vs -3.3%）
MiMedx是一家总部位于美国佐治亚州玛丽埃塔的生物医疗企业，成立于2008年。该企业以胎盘、羊膜囊、脐带等分娩组织为原料，开发可用于植皮手术的医用真皮产品，在生物再生医疗领域开展业务。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
MDXG vs ROG — 直观对比
营收规模更大
ROG
是对方的1.7倍
$118.1M
营收增速更快
MDXG
高出21.9%
5.2%
净利率更高
MDXG
高出10.6%
2.2%
两年增速更快
MDXG
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $118.1M | $200.5M |
| 净利润 | $15.2M | $4.5M |
| 毛利率 | 83.9% | 32.2% |
| 营业利润率 | 17.8% | — |
| 净利率 | 12.9% | 2.2% |
| 营收同比 | 27.1% | 5.2% |
| 净利润同比 | 104.2% | 421.4% |
| 每股收益（稀释后） | $0.10 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDXGROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $118.1M | $201.5M | ||
| Q3 25 | $113.7M | $216.0M | ||
| Q2 25 | $98.6M | $202.8M | ||
| Q1 25 | $88.2M | $190.5M | ||
| Q4 24 | $92.9M | $192.2M | ||
| Q3 24 | $84.1M | $210.3M | ||
| Q2 24 | $87.2M | $214.2M |
净利润MDXGROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $15.2M | $4.6M | ||
| Q3 25 | $16.7M | $8.6M | ||
| Q2 25 | $9.6M | $-73.6M | ||
| Q1 25 | $7.0M | $-1.4M | ||
| Q4 24 | $7.4M | $-500.0K | ||
| Q3 24 | $8.1M | $10.7M | ||
| Q2 24 | $17.6M | $8.1M |
毛利率MDXGROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 83.9% | 31.5% | ||
| Q3 25 | 83.5% | 33.5% | ||
| Q2 25 | 81.1% | 31.6% | ||
| Q1 25 | 81.2% | 29.9% | ||
| Q4 24 | 81.8% | 32.1% | ||
| Q3 24 | 81.8% | 35.2% | ||
| Q2 24 | 83.0% | 34.1% |
营业利润率MDXGROG
| Q1 26 | — | — | ||
| Q4 25 | 17.8% | 3.5% | ||
| Q3 25 | 19.5% | 7.3% | ||
| Q2 25 | 12.5% | -33.3% | ||
| Q1 25 | 9.4% | -0.2% | ||
| Q4 24 | 11.9% | -6.6% | ||
| Q3 24 | 13.3% | 6.9% | ||
| Q2 24 | 26.9% | 5.3% |
净利率MDXGROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 12.9% | 2.3% | ||
| Q3 25 | 14.7% | 4.0% | ||
| Q2 25 | 9.8% | -36.3% | ||
| Q1 25 | 8.0% | -0.7% | ||
| Q4 24 | 8.0% | -0.3% | ||
| Q3 24 | 9.6% | 5.1% | ||
| Q2 24 | 20.2% | 3.8% |
每股收益（稀释后）MDXGROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.10 | $0.20 | ||
| Q3 25 | $0.11 | $0.48 | ||
| Q2 25 | $0.06 | $-4.00 | ||
| Q1 25 | $0.05 | $-0.08 | ||
| Q4 24 | $0.05 | $-0.04 | ||
| Q3 24 | $0.05 | $0.58 | ||
| Q2 24 | $0.12 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $166.1M | $195.8M |
| 总债务越低越好 | $18.0M | — |
| 股东权益账面价值 | $256.5M | $1.2B |
| 总资产 | $342.7M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资MDXGROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $166.1M | $197.0M | ||
| Q3 25 | $142.1M | $167.8M | ||
| Q2 25 | $118.9M | $157.2M | ||
| Q1 25 | $106.4M | $175.6M | ||
| Q4 24 | $104.4M | $159.8M | ||
| Q3 24 | $88.8M | $146.4M | ||
| Q2 24 | $69.0M | $119.9M |
总债务MDXGROG
| Q1 26 | — | — | ||
| Q4 25 | $18.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $19.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益MDXGROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $256.5M | $1.2B | ||
| Q3 25 | $238.9M | $1.2B | ||
| Q2 25 | $216.6M | $1.2B | ||
| Q1 25 | $202.8M | $1.3B | ||
| Q4 24 | $193.1M | $1.3B | ||
| Q3 24 | $181.0M | $1.3B | ||
| Q2 24 | $168.0M | $1.3B |
总资产MDXGROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $342.7M | $1.4B | ||
| Q3 25 | $319.0M | $1.4B | ||
| Q2 25 | $291.1M | $1.5B | ||
| Q1 25 | $270.4M | $1.5B | ||
| Q4 24 | $263.9M | $1.5B | ||
| Q3 24 | $243.9M | $1.5B | ||
| Q2 24 | $230.2M | $1.5B |
负债/权益比MDXGROG
| Q1 26 | — | — | ||
| Q4 25 | 0.07× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.0M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | — | $1.1M |
| 自由现金流率自由现金流/营收 | — | 0.5% |
| 资本支出强度资本支出/营收 | — | 2.3% |
| 现金转化率经营现金流/净利润 | 1.64× | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流MDXGROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $25.0M | $46.9M | ||
| Q3 25 | $29.3M | $28.9M | ||
| Q2 25 | $14.4M | $13.7M | ||
| Q1 25 | $5.3M | $11.7M | ||
| Q4 24 | $18.8M | $33.7M | ||
| Q3 24 | $19.6M | $42.4M | ||
| Q2 24 | $21.8M | $22.9M |
自由现金流MDXGROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | — | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | — | $8.8M |
自由现金流率MDXGROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | — | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 4.1% |
资本支出强度MDXGROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 6.6% |
现金转化率MDXGROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 1.64× | 10.20× | ||
| Q3 25 | 1.75× | 3.36× | ||
| Q2 25 | 1.50× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 2.53× | — | ||
| Q3 24 | 2.42× | 3.96× | ||
| Q2 24 | 1.24× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDXG
| Wound | $78.7M | 67% |
| Surgical | $39.4M | 33% |
ROG
暂无分部数据
